Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 400
- 主要终点
- Number of Participants Reporting Compliance With Medication
研究概览
简要总结
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged prostate (EP). Adherence with EP therapy will be evaluated. The researchers believe that the majority of participants will report that they are compliant with therapy. The data source is a cross-sectional patient survey administered at one time point.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Aged 50 years or older
- •Residents of the United States
- •Receiving a prescription for an enlarged prostate (EP) treatment within 12 months prior to survey initiation
排除标准
- •Patients with prostate cancer
- •no health/prescription insurance
- •patients receiving medication(s) for EP on a PRN basis
研究组 & 干预措施
Patient Survey
Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
干预措施: 5ARI or AB or Combination Therapy (5ARI + AB) (Drug)
结局指标
主要结局
Number of Participants Reporting Compliance With Medication
时间窗: Cross sectional survey administered once to each participant during a 17-month study period (May 2009 to September 2010)
Compliance was calculated based on the participant's response to the following question: "In general, how many times did you miss taking your prostate medication?" Responses were measured on a 5-point scale. Participants who answered "I never miss a dose of my medication" were considered compliant. All other responses were considered non-compliant.
次要结局
未报告次要终点